|
GB0526211D0
(en)
*
|
2005-12-22 |
2006-02-01 |
Oxford Biomedica Ltd |
Viral vectors
|
|
WO2007091066A1
(en)
*
|
2006-02-07 |
2007-08-16 |
Ucl Business Plc |
Applications of non-integrating lentiviral vectors
|
|
AU2013203404B2
(en)
*
|
2007-08-03 |
2016-10-13 |
Centre National De La Recherche Scientifique (Cnrs) |
Lentiviral gene transfer vectors and their medicinal applications
|
|
AU2008285224B2
(en)
|
2007-08-03 |
2015-01-22 |
Centre National De La Recherche Scientifique (Cnrs) |
Lentiviral gene transfer vectors and their medicinal applications
|
|
HUE033517T2
(en)
*
|
2007-08-03 |
2017-12-28 |
Pasteur Institut |
Defective non-integrating lentivirus transfer vectors for vaccines
|
|
EP2205752B1
(en)
|
2007-10-25 |
2016-08-10 |
Sangamo BioSciences, Inc. |
Methods and compositions for targeted integration
|
|
US20110142880A1
(en)
*
|
2008-03-28 |
2011-06-16 |
Franck Yann Lemiale |
Lentivirus-based immunogenic vectors
|
|
WO2009131706A1
(en)
*
|
2008-04-26 |
2009-10-29 |
Yung-Nien Chang |
Site-specific-integration lentiviral vectors
|
|
JP2012520084A
(ja)
*
|
2009-03-13 |
2012-09-06 |
レンチゲン コーポレイション |
非組み込み型レトロウイルスベクターワクチン
|
|
WO2010117464A1
(en)
|
2009-04-09 |
2010-10-14 |
Sangamo Biosciences, Inc. |
Targeted integration into stem cells
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
JP2013518602A
(ja)
|
2010-02-09 |
2013-05-23 |
サンガモ バイオサイエンシーズ， インコーポレイテッド |
部分的に一本鎖のドナー分子による標的化ゲノム改変
|
|
DK2385107T3
(en)
|
2010-05-03 |
2016-12-12 |
Pasteur Institut |
Lentiviral vector-based immunological compounds against malaria
|
|
WO2012152912A1
(en)
|
2011-05-12 |
2012-11-15 |
Newvectys |
Genetically modified pig as a cancer prone model
|
|
EP2592091B1
(en)
|
2011-11-08 |
2017-09-20 |
Institut Pasteur |
High MAST2-affinity polypeptides and uses thereof
|
|
GB201202516D0
(en)
|
2012-02-13 |
2012-03-28 |
Ucl Business Plc |
Materials and methods relating to packaging cell lines
|
|
NZ700340A
(en)
|
2012-03-30 |
2017-02-24 |
Immune Design Corp |
Lentiviral vector particles having improved transduction efficiency for cells expressing dc- sign
|
|
US9713635B2
(en)
|
2012-03-30 |
2017-07-25 |
Immune Design Corp. |
Materials and methods for producing improved lentiviral vector particles
|
|
WO2014093709A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
SG11201504523UA
(en)
|
2012-12-12 |
2015-07-30 |
Broad Inst Inc |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
EP2970372B1
(en)
|
2013-03-15 |
2020-09-30 |
Celgene Corporation |
Modified t lymphocytes
|
|
CA2915842C
(en)
|
2013-06-17 |
2022-11-29 |
The Broad Institute, Inc. |
Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy
|
|
KR20160056869A
(ko)
|
2013-06-17 |
2016-05-20 |
더 브로드 인스티튜트, 인코퍼레이티드 |
바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
|
|
CA2915845A1
(en)
*
|
2013-06-17 |
2014-12-24 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
|
|
CN106062197A
(zh)
|
2013-06-17 |
2016-10-26 |
布罗德研究所有限公司 |
用于序列操纵的串联指导系统、方法和组合物的递送、工程化和优化
|
|
EP4245853A3
(en)
|
2013-06-17 |
2023-10-18 |
The Broad Institute, Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
|
WO2014204727A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
|
US20160230190A1
(en)
*
|
2013-09-17 |
2016-08-11 |
Inserm ( Institut National De La Sante Et De La Re Cherche Medicale) |
Lentiviral Vectors Having a Mutated Integrase Protein and uses Thereof
|
|
EP2878667A1
(en)
|
2013-11-29 |
2015-06-03 |
Institut Pasteur |
TAL effector means useful for partial or full deletion of DNA tandem repeats
|
|
WO2015089462A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
|
|
JP6793547B2
(ja)
|
2013-12-12 |
2020-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
|
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
|
CA2932472A1
(en)
|
2013-12-12 |
2015-06-18 |
Massachusetts Institute Of Technology |
Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
|
|
GB201322798D0
(en)
|
2013-12-20 |
2014-02-05 |
Oxford Biomedica Ltd |
Production system
|
|
SG10201809379UA
(en)
|
2014-04-25 |
2018-11-29 |
Bluebird Bio Inc |
Mnd promoter chimeric antigen receptors
|
|
US10479975B2
(en)
|
2014-06-06 |
2019-11-19 |
Bluebird Bio, Inc. |
Methods of making T cell compositions
|
|
CN106795217B
(zh)
|
2014-07-24 |
2021-08-06 |
蓝鸟生物公司 |
Bcma嵌合抗原受体
|
|
EP3031923A1
(en)
*
|
2014-12-11 |
2016-06-15 |
Institut Pasteur |
Lentiviral vector-based japanese encephalitis immunogenic composition
|
|
WO2016094867A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Protected guide rnas (pgrnas)
|
|
SG11201704727WA
(en)
|
2014-12-12 |
2017-07-28 |
Bluebird Bio Inc |
Bcma chimeric antigen receptors
|
|
CN109536474A
(zh)
|
2015-06-18 |
2019-03-29 |
布罗德研究所有限公司 |
降低脱靶效应的crispr酶突变
|
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
|
US10701165B2
(en)
|
2015-09-23 |
2020-06-30 |
Sensoriant, Inc. |
Method and system for using device states and user preferences to create user-friendly environments
|
|
WO2017060662A1
(en)
*
|
2015-10-07 |
2017-04-13 |
The Secretary Of State For Health |
Method for providing a control for use in a screen for pathogenic virus
|
|
US11479755B2
(en)
|
2015-12-07 |
2022-10-25 |
2Seventy Bio, Inc. |
T cell compositions
|
|
CN109311963A
(zh)
|
2016-04-14 |
2019-02-05 |
蓝鸟生物公司 |
救助嵌合抗原受体系统
|
|
WO2017214938A1
(zh)
*
|
2016-06-16 |
2017-12-21 |
毛侃琅 |
特异促进 bace1 基因高表达的慢病毒表达载体及应用
|
|
MA45996A
(fr)
|
2016-08-16 |
2021-06-02 |
Bluebird Bio Inc |
Variants d'endonucléase de homing du récepteur alpha de l'il-10, compositions et méthodes d'utilisation associées
|
|
WO2018039333A1
(en)
|
2016-08-23 |
2018-03-01 |
Bluebird Bio, Inc. |
Tim3 homing endonuclease variants, compositions, and methods of use
|
|
CN109923211A
(zh)
|
2016-09-08 |
2019-06-21 |
蓝鸟生物公司 |
Pd-1归巢核酸内切酶变体、组合物及使用方法
|
|
CN110050066A
(zh)
|
2016-10-17 |
2019-07-23 |
蓝鸟生物公司 |
TGFβR2核酸内切酶变体、组合物和使用方法
|
|
MX2019005277A
(es)
|
2016-11-04 |
2019-09-27 |
Bluebird Bio Inc |
Composiciones de celulas t con car anti-bcma.
|
|
KR20240046620A
(ko)
|
2016-11-17 |
2024-04-09 |
2세븐티 바이오, 인코포레이티드 |
TGFβ 신호 컨버터
|
|
RU2019120721A
(ru)
*
|
2016-12-06 |
2021-01-11 |
Блубёрд Био, Инк. |
Генная терапия для лечения мукополисахаридоза i типа
|
|
AU2017370673A1
(en)
*
|
2016-12-06 |
2019-06-27 |
Bluebird Bio, Inc. |
Gene therapy for mucopolysaccharidosis, type II
|
|
EP3357504A1
(en)
|
2017-02-02 |
2018-08-08 |
Institut Pasteur |
Functional screening of antigenic polypeptides - use for the identification of antigens eliciting a protective immune response and for the selection of antigens with optimal protective activity
|
|
EP3357506A1
(en)
|
2017-02-02 |
2018-08-08 |
Institut Pasteur |
Multiple malaria pre-erythrocytic antigens and their use in the elicitation of a protective immune response in a host
|
|
CN110446781A
(zh)
|
2017-02-15 |
2019-11-12 |
蓝鸟生物公司 |
供体修复模板多重基因组编辑
|
|
EP3630962A4
(en)
|
2017-05-25 |
2021-01-20 |
Bluebird Bio, Inc. |
CBLB ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE
|
|
WO2019070974A1
(en)
|
2017-10-04 |
2019-04-11 |
Bluebird Bio, Inc. |
PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE
|
|
EP3696272A1
(en)
|
2017-12-22 |
2020-08-19 |
Oxford BioMedica (UK) Limited |
Retroviral vector
|
|
DE102018010282A1
(de)
|
2018-01-17 |
2019-07-18 |
Immatics US, Inc. |
Verfahren zur Feststellung der Wirksamkeit von viralen Vektoren
|
|
DE102018100967B4
(de)
|
2018-01-17 |
2019-08-14 |
Immatics US, Inc. |
Verfahren zur feststellung der wirksamkeit von viralen vektoren
|
|
US12060419B2
(en)
|
2018-06-14 |
2024-08-13 |
Regeneron Pharmaceuticals, Inc. |
CD79A chimeric antigen receptors
|
|
TW202019474A
(zh)
|
2018-07-11 |
2020-06-01 |
美商西建公司 |
抗bcma嵌合抗原受體之用途
|
|
JP7450945B2
(ja)
|
2018-08-30 |
2024-03-18 |
テナヤ セラピューティクス， インコーポレイテッド |
ミオカルディンおよびａｓｃｌ１を用いた心細胞リプログラミング
|
|
WO2020072059A1
(en)
|
2018-10-04 |
2020-04-09 |
Bluebird Bio, Inc. |
Cblb endonuclease variants, compositions, and methods of use
|
|
SG11202110607WA
(en)
|
2019-04-01 |
2021-10-28 |
Tenaya Therapeutics Inc |
Adeno-associated virus with engineered capsid
|
|
EP3997226A1
(en)
|
2019-07-11 |
2022-05-18 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
|
EP3770264A1
(en)
|
2019-07-22 |
2021-01-27 |
Genethon |
Precise integration using nuclease targeted idlv
|
|
CN114401989B
(zh)
|
2019-09-20 |
2024-02-09 |
上海吉倍生物技术有限公司 |
靶向bcma的抗体及嵌合抗原受体
|
|
BR112022008522A2
(pt)
|
2019-11-05 |
2022-07-26 |
Celgene Corp |
Usos de receptores de antígeno quimérico anti-bcma
|
|
WO2021094752A1
(en)
|
2019-11-12 |
2021-05-20 |
Oxford Biomedica (Uk) Limited |
Production system
|
|
WO2021160993A1
(en)
|
2020-02-13 |
2021-08-19 |
Oxford Biomedica (Uk) Limited |
Production of lentiviral vectors
|
|
JP2023516493A
(ja)
|
2020-03-13 |
2023-04-19 |
オックスフォード バイオメディカ（ユーケー）リミテッド |
レンチウイルスベクター
|
|
WO2021212279A1
(zh)
*
|
2020-04-20 |
2021-10-28 |
广东东阳光药业有限公司 |
慢病毒的滴度提高型转移质粒
|
|
CN111534533B
(zh)
*
|
2020-04-27 |
2022-04-19 |
北京化工大学 |
一种t7rna聚合酶和t7启动子的表达系统及使用其在真核生物中表达蛋白质的方法
|
|
GB202007199D0
(en)
|
2020-05-15 |
2020-07-01 |
Oxford Biomedica Ltd |
Viral vector production
|
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
|
EP3984548A1
(en)
|
2020-10-16 |
2022-04-20 |
Institut Pasteur |
Generation of lentiviral vectors enabling routing antigens to mhc-ii pathway and inducing cd4+ and cd8+ t-cell responses immune response in a host
|
|
KR20230113755A
(ko)
|
2020-11-04 |
2023-08-01 |
셀진 코포레이션 |
선행 항암 알킬화제 요법을 받은 환자에서의 car t 세포 요법
|
|
GB202017725D0
(en)
|
2020-11-10 |
2020-12-23 |
Oxford Biomedica Ltd |
Method
|
|
WO2022120160A1
(en)
|
2020-12-04 |
2022-06-09 |
Celgene Corporation |
Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors
|
|
BR112023018329A2
(pt)
|
2021-03-12 |
2023-10-10 |
Pasteur Institut |
Genoma de vetor lentiviral recombinante, plasmídeo de dna, partícula de vetor lentiviral recombinante, célula hospedeira, composição farmacêutica e método para a preparação de partículas de vetor lentiviral
|
|
EP4322991A1
(en)
|
2021-04-16 |
2024-02-21 |
Celgene Corporation |
T cell therapy in patients who have had prior stem cell transplant
|
|
CA3225252A1
(en)
|
2021-07-14 |
2023-01-19 |
Jordan JARJOUR |
Engineered t cell receptors fused to binding domains from antibodies
|
|
GB202114530D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Retroviral vectors
|
|
GB202114534D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Novel viral regulatory elements
|
|
GB202114529D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
|
GB202114532D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral Vectors
|
|
GB202114528D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
|
CN114181972A
(zh)
*
|
2021-11-23 |
2022-03-15 |
上海本导基因技术有限公司 |
适用于难治性血管新生性眼疾病基因治疗的慢病毒载体
|
|
GB202117844D0
(en)
|
2021-12-09 |
2022-01-26 |
Oxford Biomedica Ltd |
Purification method
|
|
WO2023196997A2
(en)
|
2022-04-08 |
2023-10-12 |
2Seventy Bio, Inc. |
Multipartite receptor and signaling complexes
|
|
US20230346977A1
(en)
|
2022-04-13 |
2023-11-02 |
Universitat Autònoma De Barcelona |
Treatment of neuromuscular diseases via gene therapy that expresses klotho protein
|
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
|
WO2023230512A1
(en)
|
2022-05-26 |
2023-11-30 |
2Seventy Bio, Inc. |
Compositions for maintaining lentiviral vector and uses thereof
|
|
GB202211935D0
(en)
|
2022-08-16 |
2022-09-28 |
Oxford Biomedica Ltd |
envelope proteins
|
|
TW202423456A
(zh)
|
2022-10-21 |
2024-06-16 |
法商賽拉福柯蒂斯公司 |
表現選自denv、zikv及yfv之群之黃病毒之非結構抗原、誘導宿主中保護性cd8+t細胞免疫的多核苷酸及慢病毒載體
|
|
WO2024102954A1
(en)
|
2022-11-10 |
2024-05-16 |
Massachusetts Institute Of Technology |
Activation induced clipping system (aics)
|
|
WO2024200573A1
(en)
|
2023-03-27 |
2024-10-03 |
LAVA Therapeutics N.V. |
Nectin-4 binding agents and methods of use
|